

May 30, 2016

To,  
Listing Department,  
Dept. of Corporate Services,  
Bombay Stock Exchange Limited,  
P.J. Towers, Dalal Street, Fort,  
Mumbai: 400 001.

Respected Sir/Madam,

**Scrip code: 524500**

**Sub: OUTCOME OF THE BOARD MEETING HELD ON MONDAY, MAY 30, 2016.**

With the reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held on today, i.e. Monday, May 30, 2016, for which intimation was already given to you, the Board of Directors has:

- Approved and taken on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2016 along with the Auditors Report thereon.

Kindly find the same in order and acknowledge the receipt of the same.

Thanking You,

Yours faithfully,

For: **KILITCH DRUGS (INDIA) LIMITED**

**MUKUND MEHTA  
MANAGING DIRECTOR  
DIN: 00147876**

Encl:a/a






## DECLARATION

*[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]*

Pursuant to the requirement as specified by Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, it is hereby declared by the Auditors Report for the financial year ended as on March 31, 2016 contains unmodified opinion as provided under the Independent Auditors' Report which is attached herewith for your reference.

You are kindly requested to take the above declaration in your records.

Signed by:		
Managing Director	Mukund Mehta	 _____ Signature
Auditor of the Company	Mr. Chintan A. Ghelani Partner M. No.: 104391 M/s. A.M. Ghelani & Co. Chartered Accountants	 _____ Signature
Chairman Audit Committee	Mukesh Shah	 _____ Signature



**Place: Mumbai**

**Date: 30<sup>th</sup> May 2016**



**AJIT M. GHELANI**  
**B.Com (Hons), F.C.A., GRAD. C.W.A.**

**CHINTAN A. GHELANI**  
**B.Com (Hons), F.C.A., C.S**

**INDEPENDENT AUDITORS' REPORT**

To,  
The Board of Directors  
**Kilitch Drugs (India) Limited**

1. We have audited the accompanying Statement of Standalone Financial Results of KILITCH DRUGS (INDIA) LIMITED ("the Company") for the year ended 31<sup>st</sup> March, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.


We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting amounts disclosed in the statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

2. In our opinion and to the best of our information and according to the explanations given to us, the Statement;
  - (i) is prepared in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
  - (ii) gives a true and fair view, in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India, of the Net Loss and other financial information of the Company for the year ended 31<sup>st</sup> March, 2016.
3. The Statement includes the results for the Quarter ended 31<sup>st</sup> March, 2016 being the balancing figure between audited figures in respected of the full financial year and the published year to date figures up to the third quarter of the full financial year which were subject to limited review by us.

**For A. M. Ghelani & Company**

Chartered Accountants

FRN: 103173W


  
**Chintan Ghelani**

Partner

Membership No.: 104391

Place : Mumbai

Dated : 30<sup>th</sup> May, 2016



# KILITCH DRUGS (INDIA) LIMITED

## STATEMENT OF STANDALONE & CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2016

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

Sr. No.	Particulars	STANDALONE					CONSOLIDATED	
		Three Months Ended		Year Ended			Year ended	
		31/03/16	31/12/15	31/03/15	31/03/16	31/03/15	31/03/16	31/03/15
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	
1	<b>Income from operations</b>							
	(a) Net Sales/income from operations(net of Excise)	667.53	590.46	322.40	2082.46	1843.73	2078.84	1843.72
	(b) Other operating income	10.31	3.40	8.93	19.70	59.01	19.70	59.01
	<b>Total income from Operations (Net)</b>	<b>677.84</b>	<b>593.86</b>	<b>331.33</b>	<b>2102.16</b>	<b>1902.74</b>	<b>2098.54</b>	<b>1902.73</b>
2	<b>Expenses</b>							
	(a) Cost of materials consumed	197.19	293.04	124.06	891.84	648.59	891.84	648.59
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	29.53	(44.35)	(4.69)	(18.61)	53.02	(18.61)	53.02
	(c) Employee Benefit Expenses	90.10	83.81	74.32	342.20	312.80	346.73	312.80
	(d) Depreciation and Amortisation Expenses	41.28	41.77	19.18	161.25	185.39	1004.74	185.39
	(e) Export Product Registration Charges	46.58	57.16	3.16	149.28	110.13	147.09	110.13
	(f) Other Expenses	375.15	189.14	304.57	1098.66	946.27	1168.05	959.72
	<b>Total Expenses</b>	<b>779.82</b>	<b>620.57</b>	<b>520.60</b>	<b>2624.62</b>	<b>2256.20</b>	<b>3539.85</b>	<b>2269.65</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(101.96)</b>	<b>(26.72)</b>	<b>(189.27)</b>	<b>(522.46)</b>	<b>(353.46)</b>	<b>(1441.31)</b>	<b>(366.92)</b>
4	Other Income	154.91	43.13	71.24	273.51	269.02	278.44	272.08
5	<b>Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>52.95</b>	<b>16.41</b>	<b>(118.03)</b>	<b>(248.96)</b>	<b>(84.44)</b>	<b>(1162.87)</b>	<b>(94.84)</b>
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit / (Loss) from ordinary activities before exceptional items (5-6)</b>	<b>52.95</b>	<b>16.41</b>	<b>(118.03)</b>	<b>(248.96)</b>	<b>(84.44)</b>	<b>(1162.87)</b>	<b>(94.84)</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from ordinary activities before tax (7+8)</b>	<b>52.95</b>	<b>16.41</b>	<b>(118.03)</b>	<b>(248.96)</b>	<b>(84.44)</b>	<b>(1162.87)</b>	<b>(94.84)</b>
10	Tax Expenses							
	Current Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Deferred Tax	(5.43)	(18.98)	8.69	(43.61)	(65.90)	(43.78)	(65.90)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>58.38</b>	<b>35.39</b>	<b>(126.72)</b>	<b>(205.35)</b>	<b>(18.54)</b>	<b>(1119.09)</b>	<b>(28.94)</b>
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>58.38</b>	<b>35.39</b>	<b>(126.72)</b>	<b>(205.35)</b>	<b>(18.54)</b>	<b>(1119.09)</b>	<b>(28.94)</b>
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10469.01	10674.36	9545.52	10664.71
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):							
	(a) Basic	0.44	0.27	(0.96)	(1.55)	(0.14)	(8.46)	(0.22)
	(b) Diluted	0.44	0.27	(0.96)	(1.55)	(0.14)	(8.46)	(0.22)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):							
	(a) Basic	0.44	0.27	(0.96)	(1.55)	(0.14)	(8.46)	(0.22)
	(b) Diluted	0.44	0.27	(0.96)	(1.55)	(0.14)	(8.46)	(0.22)

**Notes:**

- 1 The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on
- 2 The Company as well as the Group has operated only in one reportable segment i.e. Pharmaceuticals.
- 3 The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. The standalone figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the current financial year.

Place : Mumbai  
Date: 30th May, 2016



*Handwritten signature*

# KILITCH DRUGS (INDIA) LIMITED

## STANDALONE & CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. (In Lacs)

Particulars	Standalone		Consolidated	
	As at 31st March, 2016 [Rs.]	As at 31st March, 2015 [Rs.]	As at 31st March, 2016 [Rs.]	As at 31st March, 2015 [Rs.]
	(Audited)	(Audited)	(Audited)	(Audited)
<b><u>EQUITY AND LIABILITIES</u></b>				
<b>Shareholders' Funds</b>				
Share capital	1,323.18	1,323.18	1,323.18	1323.18
Reserves and surplus	10,469.01	10,674.36	9,545.52	10664.71
<b>Current Liabilities</b>				
Short term Borrowings	8.92	-	18.62	0.10
Trade payables	362.95	235.52	369.15	239.12
Other current liabilities	328.82	391.16	334.54	391.53
Short-term provisions	76.79	54.64	76.97	54.64
<b>TOTAL</b>	<b>12,569.67</b>	<b>12,678.86</b>	<b>11,667.98</b>	<b>12,673.28</b>
<b><u>ASSETS</u></b>				
<b>Non-Current Assets</b>				
<b>Fixed assets</b>				
Tangible assets	831.25	934.25	867.91	934.25
Intangible assets	2.81	4.11	3,372.99	4.11
Non-current investments	6,910.98	4,715.56	2,581.89	4,715.56
Deferred tax Assets (Net)	94.43	50.82	94.60	50.82
Long-term loans and advances	71.59	2,310.00	20.26	2,293.75
Other Non-current assets	-	-	3.44	3.44
<b>Current Assets</b>				
Current investments	2,312.07	2,466.87	2,312.07	2,466.87
Inventories	262.08	238.12	262.08	238.12
Trade receivables	1,636.55	1,262.30	1,636.55	1,262.30
Cash and Bank balances	251.86	498.02	274.73	498.11
Short-term loans and advances	194.53	192.55	233.22	199.69
Other Current assets	1.52	6.26	8.24	6.26
<b>TOTAL</b>	<b>12,569.67</b>	<b>12,678.86</b>	<b>11,667.98</b>	<b>12,673.28</b>

Place: Mumbai,  
Dated: 30th May, 2016



For and on Behalf of the Board

*Mukund Mehta*  
**MUKUND MEHTA**  
(Managing Director)

**AJIT M. GHELANI**  
**B.Com (Hons), F.C.A., GRAD. C.W.A.**


**CHINTAN A. GHELANI**  
**B.Com (Hons), F.C.A., C.S**

**INDEPENDENT AUDITOR'S REPORT**

To,

**THE BOARD OF DIRECTORS**  
**KILITCH DRUGS (INDIA) LTD.**

1. We have audited the accompanying Statement of Consolidated Financial Results ("the Statement") of Kilitch Drugs (India) Ltd. ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared on the basis of the related consolidated financial statements which are in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting amounts disclosed in the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
3. (i) Consolidated financial results includes one subsidiary, the financial statements of which reflect total assets of Rs. 3,390.12 lacs as at 31<sup>st</sup> March, 2016, total revenue of Rs. 40.96 lacs for the year ended 31<sup>st</sup> March, 2016 which have been audited by us.  
(ii) We have relied on the unaudited financial statements of one foreign subsidiary, whose financial statements reflect total assets of Rs. 127.22 lacs as at 31<sup>st</sup> March, 2016. The unaudited financial statements have been furnished to us by the Management and our opinion on the statement, in so far as it relates to the amounts included in respect of the said subsidiary is based solely on such unaudited financial statements certified by the management.
4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the report of the other subsidiary referred to in paragraph 3 above, the Statement:
  - (a) Includes the results of entities as given below:




**List of Subsidiaries**

1. Monarchy Healthserve Pvt. Ltd.
2. Kilitch Estro Biotech Plc.- Foreign Subsidiary

- (b) is presented in accordance with the requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
- (c) gives a true and fair view, in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India, of the consolidated Net Loss and other financial information of the group for the year ended 31<sup>st</sup> March, 2016.

For **A. M. Ghelani & Company**  
Chartered Accountants  
(Firm Registration No. 103173W)

  
**Chintan A. Ghelani**

Partner  
Membership No. 104391



Place: Mumbai  
Date: 30-05-2016